NASH cirrhosis trials and major adverse liver outcomes: Big data needed

被引:3
作者
Noureddin, Mazen [1 ]
Harrison, Stephen A. [2 ]
机构
[1] Houston Res Inst, Houston, TX USA
[2] Pinnacle Res Ctr, San Antonio, TX 78229 USA
关键词
NONALCOHOLIC STEATOHEPATITIS; DISEASE;
D O I
10.1016/j.jhep.2022.10.022
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页码:5 / 7
页数:3
相关论文
共 16 条
[1]   Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design [J].
Allen, Alina M. ;
Therneau, Terry M. ;
Ahmed, Omar T. ;
Gidener, Tolga ;
Mara, Kristin C. ;
Larson, Joseph J. ;
Canning, Rachel E. ;
Benson, Joanne T. ;
Kamath, Patrick S. .
JOURNAL OF HEPATOLOGY, 2022, 77 (05) :1237-1245
[2]   Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration [J].
Anania, Frank A. ;
Dimick-Santos, Lara ;
Mehta, Ruby ;
Toerner, Joseph ;
Beitz, Julie .
HEPATOLOGY, 2021, 73 (05) :2023-2027
[3]   Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension [J].
Chalasani, Naga ;
Abdelmalek, Manal F. ;
Garcia-Tsao, Guadalupe ;
Vuppalanchi, Raj ;
Alkhouri, Naim ;
Rinella, Mary ;
Noureddin, Mazen ;
Pyko, Maxmillan ;
Shiffman, Mitchell ;
Sanyal, Arun ;
Allgood, Adam ;
Shlevin, Harold ;
Horton, Rex ;
Zomer, Eliezer ;
Irish, William ;
Goodman, Zachary ;
Harrison, Stephen A. ;
Traber, Peter G. .
GASTROENTEROLOGY, 2020, 158 (05) :1334-+
[4]   Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update [J].
Chew, Nicholas W. S. ;
Ng, Cheng Han ;
Truong, Emily ;
Noureddin, Mazen ;
Kowdley, Kris, V .
SEMINARS IN LIVER DISEASE, 2022, 42 (03) :379-400
[5]   EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis [J].
Angeli P. ;
Bernardi M. ;
Villanueva C. ;
Francoz C. ;
Mookerjee R.P. ;
Trebicka J. ;
Krag A. ;
Laleman W. ;
Gines P. .
JOURNAL OF HEPATOLOGY, 2018, 69 (02) :406-460
[6]   Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis [J].
Frenette, Catherine ;
Kayali, Zeid ;
Mena, Edward ;
Mantry, Parvez S. ;
Lucas, Kathryn J. ;
Neff, Guy ;
Rodriguez, Miguel ;
Thuluvath, Paul J. ;
Weinberg, Ethan ;
Bhandari, Bal R. ;
Robinson, James ;
Wedick, Nicole ;
Chan, Jean L. ;
Hagerty, David T. ;
Kowdley, Kris, V .
JOURNAL OF HEPATOLOGY, 2021, 74 (02) :274-282
[7]   Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis [J].
Han, Ma Ai Thanda ;
Altayar, Osama ;
Hamdeh, Shadi ;
Takyar, Varun ;
Rotman, Yaron ;
Etzion, Ohad ;
Lefebvre, Eric ;
Safadi, Rifaat ;
Ratziu, Vlad ;
Prokop, Larry J. ;
Murad, Mohammad Hassan ;
Noureddin, Mazen .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (04) :616-+
[8]   Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials [J].
Harrison, Stephen A. ;
Wong, Vincent Wai-Sun ;
Okanoue, Takeshi ;
Bzowej, Natalie ;
Vuppalanchi, Raj ;
Younes, Ziad ;
Kohli, Anita ;
Sarin, Shiv ;
Caldwell, Stephen H. ;
Alkhouri, Naim ;
Shiffman, Mitchell L. ;
Camargo, Marianne ;
Li, Georgia ;
Kersey, Kathryn ;
Jia, Catherine ;
Zhu, Yanni ;
Djedjos, C. Stephen ;
Subramanian, G. Mani ;
Myers, Robert P. ;
Gunn, Nadege ;
Sheikh, Aasim ;
Anstee, Quentin M. ;
Romero-Gomez, Manuel ;
Trauner, Michael ;
Goodman, Zachary ;
Lawitz, Eric J. ;
Younossi, Zobair .
JOURNAL OF HEPATOLOGY, 2020, 73 (01) :26-39
[9]  
Le P, 2022, CLIN GASTROENTEROL H
[10]   Placebo effect on progression and regression in NASH: Evidence from a meta-analysis [J].
Ng, Cheng Han ;
Xiao, Jieling ;
Lim, Wen Hui ;
Chin, Yip Han ;
Yong, Jie Ning ;
Tan, Darren Jun Hao ;
Tay, Phoebe ;
Syn, Nicholas ;
Foo, Roger ;
Chan, Mark ;
Chew, Nicholas ;
Tan, Eunice Xx ;
Huang, Daniel Q. ;
Dan, Yock Young ;
Tamaki, Nobuharu ;
Siddiqui, Mohammad Shadab ;
Sanyal, Arun J. ;
Loomba, Rohit ;
Noureddin, Mazen ;
Muthiah, Mark D. .
HEPATOLOGY, 2022, 75 (06) :1647-1661